- AR and PI3K genomic profiling of cell-free DNA can identify poor responders to Lutetium-177-PSMA among patients with metastatic castration-resistant prostate cancer(2023)
Auteurs: Jan Vanwelkenhuyzen, Eva Van Bos, Siska Van Bruwaene, Karl Lesage, Alex Maes, Sezgin Üstmert, Filip Lavent, Laurence Beels, Henrik Grönberg, Piet Ost, et al.
Pagina's: 63 - 66
- Development of an androgen receptor (AR) splice variant targeting, cell-free RNA and treatment-predictive biomarker assay for men with metastatic castration-resistant prostate cancer (mCRPC)(2022)
Auteurs: Jan Vanwelkenhuyzen
Aantal pagina's: 1
- Tissue- and blood-derived genomic biomarkers for metastatic hormone-sensitive prostate cancer : a systematic review(2021)
Auteurs: Jan Vanwelkenhuyzen, Matthew P. Deek, Phuoc T. Tran, Evan Warner, Alexander W. Wyatt, Edmond M. Kwan, Nicolaas Lumen, Bram De Laere, Piet Ost
Pagina's: 914 - 923
- Multifocality in prostate cancer : implications for PAM50 subtyping using an index lesion-only approach(2021)
Auteurs: Jan Vanwelkenhuyzen, Nicolaas Lumen, Kathleen Marchal, Piet Ost, Bram De Laere
Aantal pagina's: 1
- Tracking the origins of metastatic seeding in de novo metastatic prostate cancer(2020)
Auteurs: Kim Van der Eecken, Evan Warner, Nicolaas Lumen, Matti Annala, Andrew Murtha, Elena Schönlau, Nicolette Fonseca, Cameron Herberts, Jan Vanwelkenhuyzen, Wesley Verla, et al.
Aantal pagina's: 1